Combining health and social protection measures to reach the ultra ...

Research resources
We encourage other national governments to follow this lead
and fund a broad portfolio of research in this area. Some
countries are already supporting their scientists to research the
male reproductive system and develop methods to regulate
male fertility, but governments need to do more in terms of
funding, networking, partnering and political support. It is now
clearly apparent that only through the combined efforts of
scientists, not-for-profit research organizations, governments
and international organizations will the hope of greater access
to family planning through delivery of methods for men to use
be realized. We are strongly committed to this goal and
encourage greater public-sector involvement and investment in
this important area of research. ❏
The author is a staff member of the World Health
Organization. The author alone is responsible for the views
expressed in this publication and they do not necessarily
represent the decisions or the stated policy of the World Health
Organization.
Kirsten M Vogelsong is a scientist in the Department of
Reproductive Health and Research at the World Health Organization
in Geneva, Switzerland. She manages a portfolio of activities related
to the research and development of new methods of contraception,
with a focus on male sexual and reproductive health and fertility
regulation. Dr Vogelsong received a BA degree from Penn State and
a PhD in Neurobiology and Physiology from Northwestern University.
She has previously worked in academic research laboratories and in
project management at the United States Agency for International
Development’s Office of Population.
Henry L Gabelnick is the Executive Director of CONRAD and also
a professor in the Department of Obstetrics and Gynaecology at
Eastern Virginia Medical School. CONRAD has as its mission the
improvement of reproductive health with emphasis on developing
countries. Dr Gabelnick received BS and MS degrees from MIT and
his PhD from Princeton University. He currently is the President of
the Society for the Advancement of Reproductive Care. He has also
served on the boards of the Alliance for Microbicide Development,
Biosyn, Inc. and the International Partnership for Microbicides.
Eberhard Nieschlag is currently President of the German Society
of Andrology. Following his studies of Medicine in Bonn and Munich
and Biochemistry in London, Professor Nieschlag worked at various
departments of Internal Medicine of University Hospitals in Germany
and at the Reproduction Research Branch at the NIH in Bethesda.
He is specialized in internal medicine, endocrinology and andrology.
He was Director of the Max-Planck Clinical Research Unit for
Reproductive Medicine at the University of Muenster from 1980 to
1988 and has since then been Director of the Institute of
Reproductive Medicine of the University of Münster, which is a longstanding
WHO Collaborating Centre for Research in Male
Reproduction and a training centre of the European Academy of
Andrology. For many years, Professor Nieschlag was a member of the
WHO Steering Committee for the Regulation of Male Fertility and
was its Chairman from 1985 to 1990. He was President of the
German Society of Endocrinology, the International Society of
Andrology, the European Academy of Andrology the German Society
for Reproductive Medicine. The most recent of the many awards
Professor Nieschlag received is the Distinguished Andrologist 2007
of the American Society of Andrology.
References
1.
United Nations Department of Economic and Social Affairs, Population
Division. World Contraceptive Use 2005, 2005. Available at website
http://www.un.org/esa/population/publications/contraceptive2005/WCU2005.h
tm (accessed July 2007).
2.
Return of the Population Growth Factor – Its Impact Upon the Millennium
Development Goals, 2007. Report of hearings by the All Party Parliamentary
Group on Population, Development and Reproductive Health, House of
Commons, London.
3.
The World Bank. Population issues in the 21st century – the role of the World
Bank. Health, Nutrition and Population Discussion Paper, 2007.
4.
Heinemann K et al. Attitudes toward male fertility control: results of a
multinational survey on four continents. Human Reproduction, 2005,
20(2):549-556.
5.
Martin CW et al. Potential impact of hormonal male contraception: crosscultural
implications for development of novel preparations. Human
Reproduction, 2000, 15(3):637-645.
6.
ICPD Programme of Action, paragraph 12.14. Available at website
http://www.unfpa.org/icpd/icpd_poa.htm#ch12b (accessed July 2007).
7.
Gardner R, Blackburn RD, Upadhay UD. Closing the condom gap. Population
Reports, April 1999, Series H, No 9. Baltimore, Johns Hopkins University
School of Public Health, Population Information Program.
8.
Upadhay UD. New contraceptive choices. Population Reports, April 2005,
Series M, No. 19. Baltimore, Johns Hopkins Bloomberg School of Public
Health, The INFO project. Available at website
http://www.populationreports.org/m19/
9.
Lohiya NK et al. Vas deferens, a site of male contraception: an overview.
Asian Journal of Andrology, 2001, 3:87-95.
10.
Sokal DC. Recent research on vasectomy techniques. Asian Journal of
Andrology, 2003, 5:227-230.
11.
World Health Organization Task Force on Methods for the Regulation of Male
Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal
men. The Lancet, 1990, 336:955-959.
12.
World Health Organization Task Force on Methods for the Regulation of Male
Fertility. Contraceptive efficacy of testosterone-induced azoospermia and
oligozoospermia in normal men. Fertility and Sterility, 1996, 65:821-829.
13.
Gu Y-Q et al. A multicenter contraceptive efficacy study of injectable
testosterone undecanoate in healthy Chinese men. Journal of Clinical
Endocrinology & Metabolism, 2003, 88:562-568.
14.
Meriggiola MC, Farley TM, Mbizvo MT. A review of androgen-progestin
regimens for male contraception. Journal of Andrology, 2003,
24(4):466-483.
15.
Wenk M, Nieschlag E. Male contraception: a realistic option? European
Journal of Contraception and Reproductive Health Care, 2006,
11:69-80.
16.
Kamischke A et al. Intramuscular testosterone undecanoate and
norethisterone enanthate in a clinical trial for male contraception. Journal of
Clinical Endocrinology & Metabolism, 2001, 86:303-309.
17.
Kamischke A et al. An effective hormonal male contraceptive using
testosterone undecanoate with oral or injectable norethisterone preparations.
Journal of Clinical Endocrinology & Metabolism, 2002, 87:530-539.
18.
Meriggiola MC et al. Norethisterone enanthate plus testosterone undecanoate
for male contraception: effects of varions injection intervals on
spermatogenesis, reproductive hormones, testis and prostate. Journal of
Clinical Endocrinology & Metabolism, 2005, 90:2005-2014.
19.
Nieschlag E, Behre HM. Testosterone in male contraception. In: Nieschlag and
Behre (eds), Testosterone: Action, Deficiency, Substitution, 2nd edition,
1998, Springer Heidelberg, pp.513-528.
20.
10th Summit Meeting Consensus: Recommendations for regulatory approval
for hormonal male contraception. International Journal of Andrology, 2007,
30:63-64.
130 ✜ Global Forum Update on Research for Health Volume 4